Provectus Signs LOI for Cancer Drug with Boehringer Ingelheim China

Provectus Biopharma, a clinical stage oncology pharma headquartered in Tennessee, has signed an LOI with Boehringer Ingelheim (China) Investment Co. The LOI proposes that Boehringer will support Provectus' efforts to register PV-10, the company's lead cancer molecule, in China. In return, Boehringer will have first priority to collaborate in Provectus' China commercialization of PV-10. One year ago, Provectus signed an LOI with Sinopharm for China rights to PV-10. The agreement, which has been extended several times, will expire in two weeks. More details.... Stock Symbol: (NYSE: PCVT) Share this with colleagues: // //